Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$1,149 Mln
P/E Ratio
--
P/B Ratio
4.48
Industry P/E
--
Debt to Equity
1.8
ROE
-0.33 %
ROCE
-13.1 %
Div. Yield
0 %
Book Value
3.98
EPS
-1.45
CFO
$-59.18 Mln
EBITDA
$-437.40 Mln
Net Profit
$-791.81 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Tandem Diabetes Care (TNDM)
| -53.19 | -12.05 | -55.08 | -48.85 | -47.32 | -25.17 | -18.70 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Tandem Diabetes Care (TNDM)
| 21.58 | -34.19 | -70.14 | 57.32 | 60.51 | 56.99 | 1,484.72 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 15.10 | 10,391.68 | 14.66 | 12.69 | |
| 71.01 | 9,766.86 | 94.68 | 2.52 | |
| 152.15 | 8,196.06 | -- | -25.23 | |
| 277.35 | 10,728.90 | 770.42 | 1.2 |
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi... insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. Address: 12400 High Bluff Drive, San Diego, CA, United States, 92130 Read more
President, CEO & Director
Mr. John F. Sheridan
President, CEO & Director
Mr. John F. Sheridan
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Tandem Diabetes Care Inc (TNDM) stood at $ 968 Mln as on 31-Dec-24
The share price of Tandem Diabetes Care Inc (TNDM) is $16.86 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Tandem Diabetes Care Inc (TNDM) has given a return of -47.32% in the last 3 years.
Tandem Diabetes Care Inc (TNDM) has a market capitalisation of $ 1,149 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Tandem Diabetes Care Inc (TNDM) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Tandem Diabetes Care Inc (TNDM) and enter the required number of quantities and click on buy to purchase the shares of Tandem Diabetes Care Inc (TNDM).
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. Address: 12400 High Bluff Drive, San Diego, CA, United States, 92130
The CEO & director of Mr. John F. Sheridan. is Tandem Diabetes Care Inc (TNDM), and CFO & Sr. VP is Mr. John F. Sheridan.
There is no promoter pledging in Tandem Diabetes Care Inc (TNDM).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,070
|
|
|
1,049
|
|
|
978
|
|
|
820
|
| Tandem Diabetes Care Inc. (TNDM) | Ratios |
|---|---|
|
Return on equity(%)
|
-33.3
|
|
Operating margin(%)
|
-10.56
|
|
Net Margin(%)
|
-10.21
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Tandem Diabetes Care Inc (TNDM) was $0 Mln.
$-0.40
(
